Inhibikase Therapeutics (IKT) Proxy Filing summary

Executive summary

• Special Meeting scheduled for January 3, 2025, to be held virtually, with voting on four key proposals impacting capital structure and compensation.

• Proposals include increasing authorized common stock, amending the equity incentive plan, repricing stock options, and changing voting requirements for future amendments.

• The Board unanimously recommends voting in favor of all proposals, citing alignment with business needs and shareholder interests.

• Recent private placement raised $110 million, necessitating an increase in authorized shares to fulfill contractual obligations and support future growth.

Voting matters and shareholder proposals

• Proposal 1: Increase authorized common stock from 100,000,000 to 500,000,000 shares to support warrant exercises and future financing.

• Proposal 2: Amend 2020 Equity Incentive Plan to add 27,453,993 shares for employee and director equity awards, restoring pre-dilution ownership levels.

• Proposal 3: Reprice certain outstanding stock options to $1.26 per share to address retention and competitiveness.

• Proposal 4: Eliminate the 66 2/3% supermajority vote requirement for amending capital structure, reducing it to a simple majority.

• Board recommends voting FOR all proposals; each proposal has specific voting thresholds and implications for governance and capital flexibility.

Board of directors and corporate governance

• Board supports all proposals, emphasizing the need for flexibility in capital management and talent retention.

• Board compensation includes cash retainers and annual equity grants; non-employee directors receive both cash and stock options.

• Board aims to align governance practices with shareholder interests and market standards.